证券代码：688690 证券简称：纳微科技 公告编号：2023-053 苏州纳微科技股份有限公司 关于参加2023半年度制药及生物制品行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （http://roadshow.sseinfo.com/） 会议线上交流时间：2023 年 9 月 7 日(星期四) 下午 13:00-15:00 会议召开方式：线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心 投资者可于 2023 年 9 月 6 日(星期三)16:00 前通过电话或投资者关系邮箱 （ir@nanomicrotech.com）将需要了解和关注的问题提前提供给公司。公司将在文 字互动环节对投资者普遍关注的问题进行回答。 二、 说明会召开的时间、方式 苏州纳微科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 25 日发布 公司 2023 半年度报告，为便于广大投资者更全面深入地了解公司 2023 半年度经营 成果、财务状况、发展理念，公司参与了由上交所主办 ...

Tax and Financial Assets - The company recognizes deferred tax assets for deductible temporary differences, carryforward losses, and tax credits, provided it is probable that future taxable income will be available to utilize these benefits[1] - Deferred tax liabilities are recognized for all taxable temporary differences, except for those arising from initial recognition of goodwill or transactions that do not affect accounting or taxable profit[1] - The company applies a 15% reduced corporate income tax rate for its parent company and certain subsidiaries due to their status as high-tech enterprises[9] - Subsidiaries classified as small and micro enterprises are eligible for a reduced corporate income tax rate of 20% on taxable income between RMB 1 million and RMB 3 million from 2022 to 2024[9] - The company's bank acceptance notes decreased from RMB 17,129,338.35 at the beginning of the period to RMB 14,010,198.60 at the end of the period[13] - The company's large-denomination certificates of deposit due within one year amounted to RMB 35,000,000.00, with a face interest rate of 3.9875% and an actual interest rate of 3.9875%, maturing on January 5, 2024[59] - Total fixed-term deposits decreased from 403 million RMB to 258 million RMB, with varying interest rates ranging from 3.35% to 3.9875%[62] - Trading financial assets decreased by 75.43% to 3,528.11 million, accounting for 1.72% of total assets, mainly due to the maturity of structured deposits held at the end of the previous year[118] - Receivables financing increased by 65.58% to 1,243.82 million, accounting for 0.61% of total assets, driven by an increase in bank acceptance bills issued by high-credit-rated listed joint-stock banks[118] - Non-current assets due within one year surged by 1,243.60% to 15,662.45 million, accounting for 7.65% of total assets, primarily due to large certificates of deposit maturing within one year[118] Accounts Receivable and Inventory - The company's accounts receivable with an aging of 1 year or less amounted to RMB 251,997,402.55[15] - The company fully provided for bad debts of RMB 101,150.00 for two accounts receivable, as they are expected to be unrecoverable[18] - Accounts receivable totaled 260,700,055.45 RMB, with a bad debt provision of 14,029,616.11 RMB, representing a provision ratio of 5.38%[19] - Inventory value at the end of the period was 266,407,603.17 RMB, with a total inventory impairment provision of 19,347,107.14 RMB[32] - The company's other receivables at the end of the period amounted to RMB 4,968,911.54, an increase from the beginning of the period's RMB 4,596,481.29[46] - The company's contract assets at the end of the period amounted to RMB 2,388,928.25, with a provision for impairment of RMB 124,770.61[56] R&D and Technological Innovation - The company achieved a technological breakthrough with the UniSil HP series, offering large pore volumes exceeding 1.0mL/g, suitable for bio-macromolecule applications[34] - The UniGel-65Q HC product, a strong anion exchange chromatography medium, was launched, featuring high capacity, alkali resistance, and low back pressure[34] - The company developed a single-dispersion conductive gold ball technology, enabling the production of core-shell structured conductive gold balls with strong metal-polymer bonding[34] - The company has independently developed a high-capacity, alkali-resistant, and pressure-resistant Protein A affinity chromatography medium, which is mainly used for the separation of antibody and Fc-containing protein macromolecules. This product has broken through core preparation technologies such as soft and hard gel matrix, surface hydrophilic modification, and ligands, achieving stable scale-up production. The hard gel matrix Protein A affinity chromatography medium has higher mechanical strength, breaking the traditional 15cm column height limit, making it more suitable for industrial continuous production[37] - The company has developed a high-performance liquid chromatography column manufacturing and application technology, with its subsidiary, Napu Analysis, independently developing and improving the BioCore product series for the chromatographic characterization of antibodies and protein macromolecules. The company has launched several new products, including the ChromCore UHPLC (1.8 µm) series, BioCore RP-1000 column, and ChromCore HP C18(10 µm) column[39] - The company's subsidiary, Sepu Instruments, has independently developed protein chromatography system-related technologies, including high-pressure infusion pumps, UV detectors, and control and operation software. The company has launched the Truesynt™ nucleic acid synthesis system, a laboratory-level, fully automated phosphoramidite-based oligonucleotide synthesizer system[40] - The company has applied for 6 new invention patents and obtained 12 invention patents in the reporting period, with a cumulative total of 156 invention patent applications and 62 granted invention patents[39] - The company's R&D investment in the reporting period was RMB 83.3558 million, a 112.95% increase compared to the same period last year. The R&D investment accounted for 28.24% of the company's operating revenue, an increase of 14.92 percentage points compared to the same period last year[42] - The company's R&D model emphasizes independent development, with a focus on specific areas and collaboration with experts for technological breakthroughs[76] - The company has established a comprehensive R&D and industrialization system for microsphere precision preparation, capable of producing microspheres ranging from a few nanometers to over a thousand micrometers in size[94] - The company's single-disperse chromatography fillers and separation media have achieved rapid sales growth, breaking the monopoly of foreign companies and starting to export abroad[94] - The company's chemical luminescence magnetic beads have passed performance certifications from several leading IVD companies in China and have achieved small-scale commercial supply[97] - The company's products for liquid crystal panel spacers have become a significant breakthrough in domestic production, previously monopolized by a few Japanese companies[97] - The company has introduced several experienced management and technical talents from the life sciences industry to enhance its competitiveness in sales, marketing, and application technology[97] - The company has successfully broken through the technical challenges of precise microsphere preparation, achieving precise control over particle size, pore size, and surface properties, and has applied these products in fields such as biopharmaceuticals, analytical testing, in vitro diagnostics, and flat panel displays[102] - The company has established a comprehensive R&D, application, and industrialization system for microsphere preparation technology, and is one of the few companies globally capable of large-scale production of both inorganic and organic high-performance nanosphere materials[102] - The company's products include chromatography fillers, separation media, and purification instruments for biopharmaceutical separation and purification, as well as microspheres for LCD panel spacing and in vitro diagnostics[102] - The company's chromatography fillers and separation media are widely used in the large-scale separation and purification of organic small molecules, peptides, antibiotics, and proteins, as well as in laboratory analytical testing[104] - The company's liquid chromatography columns and sample preparation products are based on its proprietary monodisperse microsphere materials and surface modification platform technology, offering high separation selectivity and column efficiency[107] - The company provides protein purification systems and oligonucleotide synthesis systems, which are used for the analysis and purification of proteins, peptides, and nucleic acids[107] - The company's microsphere materials for flat panel displays include spacer microspheres, conductive gold balls, and black balls, which are used in LCD panel thickness control and other optoelectronic applications[107] - The company's magnetic beads and other microspheres for in vitro diagnostics are used in nucleic acid extraction, chemiluminescence, protein purification, and cell sorting[107] - The company's R&D expenses for the reporting period totaled 83.3558 million yuan, a year-on-year increase of 112.95%, primarily due to the continuous recruitment of high-end R&D talent, expansion of the R&D team, and implementation of equity incentives[149] - New generation hybrid silica gel chromatography filler with higher separation and purification performance than inorganic silica gel, significantly reducing the purification cost of related drugs[165] - New soft gel Protein A affinity chromatography medium with improved alkali resistance, lower back pressure, and stable bed height compared to the current main product NMab Pro[165] - New cation exchange chromatography medium with higher dynamic binding capacity, better resolution, and stronger salt tolerance compared to the current main product UniGel-80SP[165] - Nucleic acid synthesis carrier with performance reaching or exceeding international well-known brands[165] - Hydroxyapatite chromatography medium with better sphericity, lower back pressure, and narrower pore size distribution compared to competitors[165] - Anti-A/Anti-B affinity chromatography medium with performance reaching or exceeding international well-known brands[165] - The company has invested 977.47 million yuan in the development of a new generation of high-performance cation exchange chromatography media, with a cumulative investment of 4,535.55 million yuan, expected to launch by the end of the year[182] - A new high-capacity, alkali-resistant Protein A affinity chromatography medium has been developed, with a total investment of 1,655.14 million yuan, and is planned to be launched to the market[182] - The company has launched UniSil HP large-pore series chromatography fillers for BioSEC applications, with a total investment of 3,848.89 million yuan in silica gel chromatography filler upgrades and new product development[182] - The company has developed a new type of magnetic separation medium, with a total investment of 2,236.62 million yuan, and the products have entered the trial sales stage[183] - The company has completed the trial production of NW Rose® high-strength polysaccharide gel microspheres, with a total investment of 2,596.26 million yuan, and the product performance is comparable to foreign products[183] - The company has developed a new high-performance anti-A and anti-B affinity filler for blood product purification, with a total investment of 3,683.21 million yuan, and is preparing for product launch[183] - The company has entered the small-scale trial stage for carboxyl magnetic beads used in chemiluminescence, with a total investment of 1,049.05 million yuan in IVD microsphere new product development[183] - The company has developed a 1.8-micron UHPLC BioCore SEC chromatography column, which has been used by several domestic biopharmaceutical companies with positive feedback[183] - The company's R&D team consists of 15 PhDs (7.08%), 50 master's degree holders (23.58%), and 118 bachelor's degree holders (55.66%)[185] - The company has achieved precise control over the size and distribution of microspheres, with a coefficient of variation below 3%, significantly lower than the industry standard of over 10%[186] - The company has built a combined R&D and production base of approximately 30,000 square meters in Suzhou Industrial Park and Changshu New Materials Industrial Park, ensuring large-scale production capacity[188] - The company's supply cycle for chromatographic fillers is around 2 weeks, offering a significant advantage over foreign suppliers[189] - The company has developed a new series of single-dispersion large-pore silica chromatographic fillers, UniSil HP, with a pore volume exceeding 1.0 mL/g, suitable for bio-macromolecules[195] - The company's R&D investment accounted for 28.24% of its operating income, highlighting its focus on innovation and new product development[198] Market Trends and Industry Outlook - The domestic bio-pharmaceutical market is experiencing a significant trend towards localization, driven by national drug procurement policies and the need for stable supply chains[98] - The company's high-performance chromatography fillers are expected to see increased demand as the bio-pharmaceutical industry shifts towards more complex drugs like mRNA vaccines and ADCs[98] - The company is well-positioned to benefit from the aging population in China, which is expected to drive long-term growth in the bio-pharmaceutical sector[98] - The global biologics market is expected to grow from $286.4 billion in 2019 to $456.7 billion in 2024, with a CAGR of 9.8%[131] - The global oligonucleotide drug market reached $4.9 billion in 2021 and is projected to grow to $11.4 billion by 2025, with a CAGR of 23.3%[131] - The global CGT market is expected to grow from $2.08 billion in 2020 to $30.54 billion by 2025, with a CAGR of 71.2%[131] - China's biologics market is projected to reach ¥811.6 billion by 2025, with a CAGR of 18.6% from 2020 to 2025[131] - Global chromatography column production reached 4.08 million units in 2021, with a market size of $2.26 billion, expected to grow to 4.5 million units and $3.03 billion by 2025, with a CAGR of 7.61%[134] - China's chromatography column production reached 172,000 units in 2021, accounting for 4.2% of global production, with a market size of ¥1.25 billion, expected to grow to 229,000 units and ¥2.07 billion by 2025, with a CAGR of 13.44%[134] - China's in vitro diagnostics market reached ¥124.3 billion in 2021 and is projected to grow to ¥235.8 billion by 2025, with a CAGR of 17.4%[134] - The domestic chemiluminescence market in China is expected to reach ¥50 billion by 2023[134] Production and Sales - The company's production model focuses on standard products with safety stock indicators, adjusting production plans based on real-time inventory and sales forecasts[74] - The company employs a direct sales model, providing customized solutions and technical support to clients, particularly in the biopharmaceutical sector[75] - The company achieved revenue of 270 million yuan in the biopharmaceutical field, a year-on-year increase of 12.09%, with sales revenue from chromatography fillers and chromatography media products reaching 211 million yuan, a year-on-year increase of 5.45%[162] - The company's filler product revenue accounted for 71.46% of total revenue, an increase of 3.51 percentage points compared to the previous year[162] - The number of customers purchasing chromatography fillers and chromatography media products in the first half of the year was 397, an increase of 9 compared to the same period last year[162] - Revenue from chromatography fillers and chromatography media products applied to formal production or Phase III clinical projects in pharmaceutical companies was approximately 104 million yuan, accounting for 49.15% of filler and media product revenue, an increase of 8.10 percentage points compared to the same period last year[162] - Revenue from affinity and ion exchange chromatography media, mainly used for the separation and purification of macromolecular drugs, reached 141 million yuan, a year-on-year increase of 6.73%[162] - Revenue from polymer and silica gel chromatography fillers, mainly used for the separation and purification of small molecule drugs, was 58 million yuan, a year-on-year decrease of 9.92%[162] - The company added application laboratories in Boston, Beijing, and Guangzhou, and signed strategic cooperation agreements with important clients such as Joinn Laboratories, Kangfang Pharmaceutical, Jinsai Pharmaceutical, and GenScript[162] - The company's chromatography fillers and chromatography media were applied in approximately 630 projects in the first half of 2023, accounting for about 22% of the company's cumulative project applications[163] - The company has a total of 2,865 projects in various stages, including 849 in the antibody category and 435 in the vaccine category[194] Fixed Assets and Construction - Fixed assets increased from 394.9 million RMB to 421.75 million RMB, with significant additions in machinery and equipment (28.07 million RMB)[69] - Construction in progress increased from 37.2 million RMB to 64.28 million RMB, with major projects including the Changshu Nano Micro Production Line and Phase II Factory Construction[72] - The Changshu Nano Micro Production Line project saw an increase in investment from 1.42 million RMB to 1.21 million RMB, with a total budget of 65.63 million RMB[73] - The Phase II Factory Construction project increased from 28.25 million RMB to 51.51 million RMB, with a total budget of 330.08 million RMB[73] - The company's fixed assets increased from 298,652,521.24 yuan to 310,701,635.03 yuan, reflecting a growth of 4.04%[88] - Construction in progress increased by 72.79% to 6,428.45 million, accounting for 3.14% of total assets, mainly due to the construction of R&D centers and the first phase of the Zhejiang Nawei factory[118] - Right-of-use assets increased by 104.60% to 4,022.96 million, accounting for 1.96% of total assets, mainly due to increased leasing assets by subsidiary RILAS[118] - New production base construction in Pinghu, Zhejiang, with 60 acres of industrial land purchased and preliminary work completed[166] - 40 tons/year agarose microsphere chromatography medium and 10 tons/year dextran microsphere chromatography medium technical transformation project in Changshu production base, expected to be ready for acceptance by the end of Q3[166] - R&D center building under renovation, planned to be operational in the first half of 2024, with a total area of 29,400 square meters[166] Corporate Recognition and Risks - The company has been recognized as a national-level "Specialized, Refined, Distinctive, and Innovative" (专精特新) "Little Giant" enterprise in 2020[38] - The company plans to acquire 44.80% of Zhejiang Fuli Analytical Instruments Co., Ltd., a national-level "little giant" enterprise specializing in chromatography and related instruments[195] - The company has completed the vesting of 642,942 restricted shares for 127 employees under its 2022 stock incentive plan, aiming to retain talent and align interests[197] - The company faces risks related to the failure of new product development or inability to industrialize, which could impact revenue growth and profitability[198] - The company is exposed to risks of intellectual property infringement and increased competition from domestic peers, which could affect its core competitiveness[199] Non-Recurring Gains and Losses - Non-recurring gains and losses totaled 1,248.56 million, including government subsidies of 776.53 million and investment management gains of 796.

证券代码：688690 证券简称：纳微科技 公告编号：2023-048 苏州纳微科技股份有限公司 关于新增认定核心技术人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）基于公司发展需要，为加 强研发技术团队建设，进一步提升公司的创新能力和技术水平，经公司管理层研 究决定，新增认定WU CHEN（陈武）博士、米健秋博士为核心技术人员。公司于 2023年8月24日召开第二届董事会第二十五次会议审议通过《关于新增认定核心 技术人员的议案》，同意新增认定WU CHEN（陈武）博士、米健秋博士为公司核心 技术人员。本次新增认定的核心技术人员具体情况如下： WU CHEN（陈武）先生，1968年出生，美国国籍，中国科学技术大学学士，美 国爱荷华州立大学博士。1992年至2021年，先后担任美国安捷伦科技公司色谱柱 研究员、研发大师级科学家、首席科学家；2022年1月至今，历任公司硅胶产品 线研发负责人、副总经理。截至本公告披露日，WU CHEN（陈武）先生直接持有公 司股份11,9 ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-052 苏州纳微科技股份有限公司 前次募集资金使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《关于前次募集资金使用情况报告的规定》（证监发 行字[2007]500号）的规定，苏州纳微科技股份有限公司（以下简称"本公司"或"公 司"）将截至2023年6月30日的前次募集资金使用情况报告如下： 一、前次募集资金情况 （一）实际募集资金金额、资金到账时间 1、2021 年首次公开发行股票实际募集资金情况 经中国证券监督管理委员会证监许可[2021]1395 号文核准，本公司于 2021 年 6 月 向社会公开发行人民币普通股（A 股）4,400 万股，每股发行价为 8.07 元，募集资金总 额为人民币 35,508.00 万元，根据有关规定扣除不含税发行费用 4,714.39 万元后，实际 募集资金净额为 30,793.61 万元。该募集资金已于 2021 年 6 月 18 日到账。上述资金到 账情况业经容诚会计师事务所 ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-046 苏州纳微科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于2023年8月24日召开了 第二届董事会第二十五次会议、第二届监事会第二十一次会议，审议通过了《关 于使用暂时闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资 金投资项目建设、不变相改变募集资金使用用途、不影响公司正常运营及确保资 金安全并有效控制风险的前提下，使用不超过人民币1.2亿元（含本数）的闲置 募集资金进行现金管理，用于购买安全性高、流动性好的保本型理财产品或存款 类产品（包括但不限于保本型理财产品、协定性存款、结构性存款、定期存款、 大额存单、以及大额可转让存单等），使用期限不超过12个月。在上述额度和期 限内，资金可以循环滚动使用，本次现金管理事宜自董事会审议通过之日起12个 月内有效。董事会在额度范围内授权董事长行使该项投资决策权并签署相关合同 文件。独立董事发表 ...

中信证券股份有限公司 关于苏州纳微科技股份有限公司向参股公司转让资产 暨关联交易事项的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为苏州 纳微科技股份有限公司（以下简称"纳微科技"或"公司"）首次公开发行股票 并在科创板上市、向特定对象发行股票的保荐及持续督导机构，根据《证券发行 上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》、《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法规、规 范性文件的规定，对纳微科技向参股公司苏州鑫导电子科技有限公司（以下简称 "鑫导电子"）转让资产暨关联交易事项进行了审慎核查，核查情况如下： 一、对外转让资产暨关联交易事项概述 为了更加聚焦各自的业务板块，2023 年 8 月，纳微科技与参股公司鑫导电 子签署《关于苏州纳微科技股份有限公司与苏州鑫导电子科技有限公司之资产转 让协议》（以下简称"《转让协议》"），根据上述协议约定，公司向鑫导电子转让 各向异性导电胶膜（简称"ACF"）用导电微球相关专利权及设备，参照厦门嘉 学资产评估房地产估价有限公司出具的资产评估报告（嘉学评估评报字〔2023〕 8310066 ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-051 苏州纳微科技股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第一次临时股东大会 召开日期时间：2023 年 9 月 11 日 14 点 00 分 召开地点：江苏省苏州市工业园区百川街 2 号综合楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 11 日 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账 ...

中信证券股份有限公司 关于苏州纳微科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）为苏州纳微科 技股份有限公司（以下简称"公司"、"纳微科技"）首次公开发行股票并上市持续 督导期间的保荐机构。根据《中华人民共和国公司法》《中华人民共和国证券法》 《证券发行上市保荐业务管理办法（2023 年修订）》《上海证券交易所科创板股 票上市规则（2023 年 8 月修订）》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作（2023 年 8 月修订）》《科创板上市公司持续监管办法（试 行）》及《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》等有关规定，对纳微科技使用部分首次公开发行股票暂时闲 置募集资金进行现金管理事项进行了核查，核查情况及核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 4 月 21 日出具的《关于同意苏州纳 微科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕1395 号）， 公司首次向社会公开发行人民币普通股（A）股 ...

证券代码：688690 证券简称：纳微科技 公告编号：2023-049 苏州纳微科技股份有限公司 第二届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）第二届董事会第二十五次 会议于 2023 年 8 月 24 日 9:00 以线上线下相结合的方式召开。本次会议由董事 长江必旺博士主持，会议应到董事 9 名，实到董事 9 名，符合《中华人民共和国 公司法》和《苏州纳微科技股份有限公司章程》的有关规定，会议决议合法、有 效。 二、董事会会议审议情况 （一）审议通过《关于公司<2023 年半年度报告>及摘要的议案》 经审议，董事会确认公司 2023 年半年度报告的编制和审议程序符合法律、 法规、《公司章程》和公司内部管理制度的各项规定；公司 2023 年半年度报告的 内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规定，所包含 的信息能从各方面客观、真实、公允地反映出公司 2023 年半年度的经营管理和 财务状况等事项； ...

RSM 容诚 前次募集资金使用情况鉴证报告 苏州纳微科技股份有限公司 容诚专字[2023]200Z0651号 容诚会计师事务所(特殊普通合伙) 中国.北京 些码用于证明该市计报告是否由具有执业许可的会计师事务所出县， "注册会计师行业统一监管平台 (http://acc.m ofsov.cn)"进行喜指 报 告编列：京239Y9NZJ00 您可使用手机"扫一扫" 或进入 诚 . RSM 容 诚 容 诚会计师事务所(特殊普通合伙) 总所：北 京市西域区阜成门外大街22号 外经贸大厦15层 /922-926(100037 ) TEL:010- 6600 1391 FAX:010-6600 1392 E-mall bjārsmch nacomcn https //wwwrsmglobal/chlna/ 前次募集资金使用情况鉴证报告 容诚专字[2023]200Z0651号 苏州纳微科技股份有限公司全体股东： 目 录 | 序号 | r | 容 | 项码 | | --- | --- | --- | --- | | l | 前次募集资金使用情况鉴证报告 | | 1-3 | | 2 | 前次募集资金使用情况专项报告 | | ...